- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01955772
Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation. (NEPHA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
EN (enteral nutrition) or PN (parenteral nutrition) artificial nutrition will be launched at D1-D2 of the transplantation (D0 being the day of the transplantation),without taking into account the oral intake. This helps in particular to launch the EN after the stage of significant digestive problems related to the conditioning and before the mucositis appearance.
EN group: According to the HAS and SFNEP (Societe francophone nutrition clinique) recommendations and the good practice rules, a polyurethane or silicone NGT(Naso gastric tube), 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.
PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 65 years
- Men and women
- Patients undergoing myeloablative allo-SCT
- Allo-SCT genoidentical or phenoidentical 10/10
- Patients affiliated with a social security organisation
- Patients having signed the informed consent
Exclusion Criteria:
- Status of tumour progression at the moment of the allo-SCT
- Artificial nutrition begun before the inclusion
- Inability to understand the protocol (linguistic barrier, cognitive difficulties)
- Contraindication or associated pathology that does not allow to carry out EN or PN according to the protocol
- Medical history of progressive psychiatric illness
- Medical history of another progressive cancer or occurrence in the 5 previous years
- Presence of a simultaneous serious and uncontrolled disease such as severe cardiac, renal, hepatic or respiratory failure or severe sepsis
- Previous allo-SCT
- Participation in another clinical trial studying an allograft procedure, and applying modalities that are not available in routine practice (including innovative immunosuppression and graft or conditioning regimens not considered as myeloablative)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: EN (Enteral Nutrition)
NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months. PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments. |
Enteral nutrition versus parenteral nutrition
Other Names:
|
OTHER: PN (Parenteral Nutrition)
NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months. PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments. |
Enteral nutrition versus parenteral nutrition
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality related to the transplant
Time Frame: at day 100
|
at day 100
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of post-transplant complications targeting acute GVH, mucite and infections
Time Frame: 12 months after AHSCT (hematopoietic stem cell transplantation)
|
12 months after AHSCT (hematopoietic stem cell transplantation)
|
|
Overall survival and disease free survival
Time Frame: 12 months after AHSCT (hematopoietic stem cell transplantation)
|
12 months after AHSCT (hematopoietic stem cell transplantation)
|
|
Evolution of nutritional state
Time Frame: 12 months after AHSCT
|
All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM.
|
12 months after AHSCT
|
Tolerance of nutritional support mainly on digestive and hepatobiliary disorders
Time Frame: 12 months after AHSCT
|
All patients will received, whatever treatment arm, intravenous alanyl-glutamin, Dipeptiven which have AMM.
|
12 months after AHSCT
|
Engraftment rates
Time Frame: Day30, Day60, Day90 and Day180
|
Day30, Day60, Day90 and Day180
|
|
quality of life assessment
Time Frame: Day7, Day90, Day180 and Day360
|
Day7, Day90, Day180 and Day360
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: corinne Bouteloup, University Hospital, Clermont-Ferrand
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CHU-0165
- 2011-A1288-33
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloablative Allo-SCT
-
Memorial Sloan Kettering Cancer CenterWithdrawnAllo-SCT Patients | Adult Allo-SCT SurvivorUnited States
-
Heidelberg UniversityUniversity of RegensburgUnknown
-
National Taiwan University HospitalCompletedPatients Who Have Received Allo-HSCTTaiwan
-
Nanfang Hospital of Southern Medical UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsUnknownAllogeneic Hematopoietic Stem Cell Transplantation | Myeloablative | Delayed Platelet EngraftmentChina
-
Erhan AysanCompleted
-
Nordic MDS GroupUnknownMDS | SCT | MRDDenmark, Norway, Sweden
-
National Taiwan University HospitalNational Cheng-Kung University Hospital; Far Eastern Memorial Hospital; Tri-Service... and other collaboratorsTerminatedPatients Who Have Received Allo-HSCTTaiwan
-
Hadassah Medical OrganizationTerminatedGraft Versus Host Disease | Allogeneic Haplo-Stem Cell Transplatation (SCT)Israel
-
GWT-TUD GmbHCompletedMDS and AML Prior to Allogeneic SCTGermany
-
Cell Medica LtdTechnology Strategy Board, United KingdomCompletedADV Infection Post Allo-HSCTUnited Kingdom
Clinical Trials on Enteral nutrition alanyl-glutamin, Dipeptiven
-
Assiut UniversityCompleted
-
Air Force Specialized Hospital, Cairo, EgyptRecruiting
-
Centre Hospitalier Universitaire de BesanconUnknownBiomarkers | Enteral Nutrition | Intensive Care Unit
-
University of Alabama at BirminghamActive, not recruitingEnteral Feeding Intolerance | Premature; Infant, Light-for-datesUnited States
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Nanjing University School of MedicineJinling Hospital, ChinaCompletedAcute Pancreatitis | Intra-abdominal HypertensionChina
-
Shanghai Zhongshan HospitalRenJi Hospital; Shanghai 10th People's Hospital; Shanghai Tong Ren Hospital; Xinhua... and other collaboratorsSuspended
-
Société des Produits Nestlé (SPN)Completed
-
Ruijin HospitalRenJi HospitalUnknown
-
Centre Hospitalier Departemental VendeeInstitut National de la Santé Et de la Recherche Médicale, France; Ministry... and other collaboratorsTerminatedShock | Acute Respiratory FailureFrance